Analysts predict that Amneal Pharmaceuticals Inc (NYSE:AMRX) will post sales of $403.26 million for the current quarter, Zacks reports. Five analysts have made estimates for Amneal Pharmaceuticals’ earnings. The highest sales estimate is $413.50 million and the lowest is $382.50 million. Amneal Pharmaceuticals posted sales of $476.49 million during the same quarter last year, which suggests a negative year-over-year growth rate of 15.4%. The business is scheduled to announce its next quarterly earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Amneal Pharmaceuticals will report full year sales of $1.67 billion for the current year, with estimates ranging from $1.62 billion to $1.70 billion. For the next year, analysts forecast that the firm will report sales of $1.69 billion, with estimates ranging from $1.56 billion to $1.78 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Amneal Pharmaceuticals.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.05). Amneal Pharmaceuticals had a negative net margin of 3.65% and a positive return on equity of 28.20%. The business had revenue of $404.60 million for the quarter, compared to the consensus estimate of $420.12 million. During the same period in the previous year, the firm earned $0.24 EPS. The company’s revenue was down 12.5% on a year-over-year basis.

AMRX has been the topic of several analyst reports. Piper Jaffray Companies upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $11.00 price target on the stock in a report on Monday, July 8th. Svb Leerink raised shares of Amneal Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price target for the stock from $11.00 to $5.00 in a report on Monday, July 22nd. Royal Bank of Canada cut shares of Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $11.00 to $6.00 in a report on Thursday, July 11th. Raymond James cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their price target for the stock from $13.00 to $8.50 in a report on Wednesday, July 10th. Finally, Guggenheim initiated coverage on shares of Amneal Pharmaceuticals in a report on Thursday. They issued a “sell” rating and a $2.50 price target for the company. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $9.00.

Shares of AMRX stock traded down $0.01 during mid-day trading on Tuesday, reaching $3.48. 16,819 shares of the company’s stock traded hands, compared to its average volume of 1,829,185. Amneal Pharmaceuticals has a 12 month low of $2.27 and a 12 month high of $24.35. The firm has a 50 day moving average price of $2.93 and a two-hundred day moving average price of $8.34. The company has a debt-to-equity ratio of 3.66, a quick ratio of 1.41 and a current ratio of 2.17. The firm has a market capitalization of $1.04 billion, a PE ratio of 3.58, a price-to-earnings-growth ratio of 0.43 and a beta of 1.49.

In other Amneal Pharmaceuticals news, major shareholder International Ltd Fosun acquired 1,642,300 shares of the business’s stock in a transaction dated Monday, August 5th. The shares were purchased at an average price of $3.04 per share, for a total transaction of $4,992,592.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Andrew S. Boyer acquired 66,666 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average price of $2.89 per share, for a total transaction of $192,664.74. The disclosure for this purchase can be found here. Insiders bought 1,788,966 shares of company stock worth $5,377,057 in the last quarter. Company insiders own 26.34% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its stake in Amneal Pharmaceuticals by 790.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,766 shares of the company’s stock worth $56,000 after purchasing an additional 6,894 shares during the period. Bank of Montreal Can boosted its holdings in Amneal Pharmaceuticals by 87.5% in the second quarter. Bank of Montreal Can now owns 8,475 shares of the company’s stock worth $60,000 after purchasing an additional 3,954 shares during the period. First Mercantile Trust Co. boosted its holdings in Amneal Pharmaceuticals by 40.9% in the first quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock worth $169,000 after purchasing an additional 3,461 shares during the period. Atria Investments LLC acquired a new position in Amneal Pharmaceuticals in the second quarter worth $240,000. Finally, Acadian Asset Management LLC acquired a new position in Amneal Pharmaceuticals in the first quarter worth $325,000. Hedge funds and other institutional investors own 34.79% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also: Are FAANG stocks a good investment?

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.